Exothera Partners with Remedium to Scale-Up Manufacturing of Gene Therapy Drug Candidate
CDMO Exothera and biotech company Remedium are joining forces to scale up the manufacturing process for Remedium’s lead gene therapy candidate for treating osteoarthritis.
Exothera, a Belgium-based contract development and manufacturing organization (CDMO), and Remedium Bio, a US-based biotechnology company, have entered into an agreement under which the two companies will collaborate to scale-up manufacturing and demonstrate the industrialization potential of Remedium’s lead gene therapy drug candidate, AAV2-FGF18, the companies announced on March 22, 2023.
Remedium’s lead candidate is a disease-modifying gene therapy that is based on the clinically proven regenerative mechanism of fibroblast growth factor 18 (FGF18), according to Remedium in a company press release. The company is developing the gene therapy to treat osteoarthritis, a sector of rheumatology that has the largest unmet clinical need and which currently has no approved disease-modifying treatments, according to the press release.
With a 160,000-ft2 manufacturing center of excellence in Jumet, Belgium, Exothera, is well-positioned to supply clinical- and commercial-scale supplies of AAV2-FGF18, the company stated in the release. The CDMO will execute a proof-of-concept demonstration for transient expression of AAV2-FGF18 with suspension culture using a human embryonic kidney cells 293 cell line. Exothera aims to identify a high yield production process and reduce cost-of-goods for the lead candidate’s manufacturing process.
Source: Exothera
